4Pusztai L, Ayers M, Stec J, et al. Clinical application of cDNA microarrays in oncology[J]. Oncologist, 2003,3 (8) : 252-258.
5Ouo Q M. DNA microarray and cancer[J]. Curr Opin Oncol,2003,15(1):36 -43.
6Palmieri A, Pezzetti F, Brunelli G, etal. A comparison between genetic portraits of normal osteoblasts and osteosarcoma cell lines[J]. IndianJ Dent Res,2009,20(1):52-59.
7Li G, Zeng H, Chen L, et al. An integrative multi-platform analysis for discovering biomarkers of osteosarcoma[J]. BMC Cancer, 2009,16(9) : 150.
9Zucchini C, Rocchi A, Manara M C, et al. Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell linesEJ~. Int J Oncol,2008,32(1):17 -31.
10Chen X, Yang T T, Qiu X C, etal. Gene expression profiles of human osteosarcoma cell sublines with different pulmonary metastatic potentials[J]. Cancer Biol Ther, 2010,11 ( 2 ) :90- 95.
5wAza-Blane P, Cooper CL, Wagner K, Batalov S, Oeveraux QL, Cooke MP. Identication of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening[J]. Mol Cell, 2003, 12 (3) : 627-637.
6Shimada Y, Sato F, Shimizu K, Tsujimoto G, Tsukada K. cDNA microarray analysis of esophageal cancer: discoveries and prospects [J]. Gen Thorae Cardiovasc Surg, 2009, 57 (7) : 347-356.
7Lisle JW, Choi JY, Horton JA, Allen M J, Damron TA. Metastatic osteosarcoma gene expression differs in vitro and in vivo [ J]. Clin Orthop Relat Res, 2008, 466 (9) : 2071-2080.
8Strandh M, Johansson T, Lofstedt C. Global transcriptional analysis of pheromone biosynthesis-related genes in the female turnip moth, Agrotis segetum (Noctuidae) using a custom-made cDNA microarray [J]. Insect Biochem Mol Biol, 2009, 39 (7) : 484- 489.
9Zwerner JP, Guimbellot J, May WA. EWS/FLI function varies in different cellular backgrounds [J].Exp Cell Res, 2003, 290 (2) : 414-419.
10Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, et al. Development of Ewingg sarcoma from primary bone marrow-derived mesenchymal progenitor cells [ J ]. Cancer Res, 2005, 65 (24) :11459-11468.
3Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges[J]. Lancet Neurol, 2012,11 (10):891- 905.
4Mahadevan M S. Myotonie dystrophy: is a narrow focus obscuring the rest of the field[J]. Curr Opin Neurol, 2012, 25 (5) :609-613.
5Udd B, Meola G, Krahe R, et al. Myotonic dystrophy type 2 (DM2) and related disorders report of the 180th ENMC workshop including guidelines on diagnostics and management 3- 5 December 2010, Naarden, the Netherlands[J]. Neuromuscul Disord,2011,21(6) :443-450.
6Vihola A, Bachinski L L, Sirito M, et al. Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2 [J]. Acta Neuropatho, 2010,119(4) :465 -479.
7Todd P K, Paulson H L. RNA mediated neurodegeneration in repeat expansion disorders[J]. Ann Neurol, 2010,67(3):291- 300.
8Sobczak K, Wheeler T M, Wang W, et al. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy [J]. MolTher,2013,21(2):380-387.
9Chen W, Wang Y, Abe Y, etal. Haploinsuffciency for Znf9 in Znf9 +/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy[J]. J Mol Biol, 2007,368 ( 1 ):8- 17.
10Raheem O, Olufemi S, gachinski L, et al. Mutant (CCTG)n expansion causes abnormal expression of ZNF9 in myotonic dystrophy type2 (DM2)[J]. Am J Pathol,2010,177(6):3025- 3036.
